Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro

被引:4
作者
Scott, D. J.
Parkes, A. T.
Ponchel, F.
Cummings, M.
Poola, I.
Speirs, V.
机构
[1] Univ Leeds, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England
[2] Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA
关键词
breast cancer; tamoxifen resistance; microarray;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Tamoxifen resistance (TAMr) in breast cancer is a serious clinical dilemma, with no satisfactory explanation. We hypothesised that changes in the expression of steroid hormone receptors (ER alpha, ERSS), their downstream target genes (PR, pS2) and their associated co-regulators (AIB-1, SRC-1, SRA, NCoR-1, SMRT and REA) could be related to the acquisition of TAMr. To test this hypothesis, we developed in vitro TAMr cell line models by continuous exposure of MCF-7 cells to 4-hydroxytamoxifen (4-HT) over 12 (MCF-7(MMU1)) and 21 (MCF-7(MMU2)) months, respectively and examined the expression of the above by Western blotting and immunohistochemistry. In addition, we further examined the changes in global gene expression in TAMr cells in comparison with TAM-sensitive cells by microarray analysis. We report here that acquisition of TAMr is associated with changes in the expression of PR, pS2 and several co-activators, but not ERs. In addition, genes associated with cell cycle, cell adhesion and extracellular matrix, were up-regulated while those associated with apoptosis or growth factors/hormones were down-regulated. Based on our results, it appears that increased co-activator expression, in concert with alterations in genes associated with controlling cell proliferation and survival contribute to TAMr in breast cancer.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 61 条
[1]
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]
Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[3]
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[4]
Badia E, 2000, CANCER RES, V60, P4130
[5]
Loss of ERβ expression as a common step in estrogen-dependent tumor progression [J].
Bardin, A ;
Boulle, N ;
Lazennec, G ;
Vignon, F ;
Pujol, P .
ENDOCRINE-RELATED CANCER, 2004, 11 (03) :537-551
[6]
Bautista S, 1998, CLIN CANCER RES, V4, P2925
[7]
Quantification of estrogen receptor α and β expression in sporadic breast cancer [J].
Bièche, I ;
Parfait, B ;
Laurendeau, I ;
Girault, I ;
Vidaud, M ;
Lidereau, R .
ONCOGENE, 2001, 20 (56) :8109-8115
[8]
Bouras T, 2001, CANCER RES, V61, P903
[9]
BRUNNER N, 1993, CANCER RES, V53, P3229
[10]
Chan CMW, 1999, CLIN CANCER RES, V5, P3460